fexaramine profile

fexaramine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5326713
CHEMBL ID	192966
CHEBI ID	80003
SCHEMBL ID	17083218
MeSH ID	M0450340

Synonym
2-propenoic acid, 3-(3-((cyclohexylcarbonyl)((4'-(dimethylamino)(1,1'-biphenyl)-4-yl)methyl)amino]phenyl)-, methyl ester
unii-wtg9gfa65u
wtg9gfa65u ,
BRD-K34170797-001-01-1
gtpl2744
methyl (z)-3-[3-[cyclohexanecarbonyl-[[4-(4-dimethylaminophenyl)phenyl]methyl]amino]phenyl]prop-2-enoate
574013-66-4
FEX ,
fexaramine
DB02545
NCGC00167776-01
bdbm50167161
(e)-3-{3-[cyclohexanecarbonyl-(4''-dimethylamino-biphenyl-4-ylmethyl)-amino]-phenyl}-acrylic acid methyl ester
CHEMBL192966 ,
chebi:80003 ,
CS-3884
AKOS024457169
3-[3-[(cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester
AC-31467
HY-10912
3-[3-[(cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester
SCHEMBL17083218
mfcd09971007
fexaramine, >=98% (hplc)
(e)-methyl 3-(3-(n-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
BCP15784
methyl (e)-3-(3-(n-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
EX-A2246
HMS3677H09
methyl (2e)-3-(3-(n-((4-(4-(dimethylamino)phenyl)phenyl)methyl)cyclohexaneamido)phenyl)prop-2-enoate
2-propenoic acid, 3-(3-((cyclohexylcarbonyl)((4'-(dimethylamino)(1,1'-biphenyl)-4-yl)methyl)amino)phenyl)-, methyl ester
(e)-methyl 3-(3-(n-((4'-(dimethylamino)-(1,1'-biphenyl)-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
3-(3-((cyclohexylcarbonyl)-((4'-(dimethylamino)-(1,1'-biphenyl)-4-yl)methyl)amino)phenyl)-2-propenoicacidmethylester
2197131-49-8
AS-35318
2-propenoic acid,3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-,methyl ester
HMS3413H09
Q19597241
methyl (2e)-3-{3-[n-({4-[4-(dimethylamino)phenyl]phenyl}methyl)cyclohexaneamido]phenyl}prop-2-enoate
3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid, methyl ester
methyl (e)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]phenyl]prop-2-enoate
S6413
A904608
(e)-methyl 3-(3-(n-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
ZXA01366
DTXSID80870369

Class	Description
biphenyls	Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	25.1189	0.0040	23.8416	100.0000	AID485290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile acid receptor	Homo sapiens (human)	EC50 (µMol)	0.1542	0.0040	1.4191	10.0000	AID1893165; AID240037; AID254619; AID254620; AID512618; AID694036
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of very-low-density lipoprotein particle remodeling	Bile acid receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bile acid receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoter	Bile acid receptor	Homo sapiens (human)
intracellular glucose homeostasis	Bile acid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
inflammatory response	Bile acid receptor	Homo sapiens (human)
cell-cell junction assembly	Bile acid receptor	Homo sapiens (human)
Notch signaling pathway	Bile acid receptor	Homo sapiens (human)
bile acid metabolic process	Bile acid receptor	Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathway	Bile acid receptor	Homo sapiens (human)
regulation of low-density lipoprotein particle clearance	Bile acid receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
negative regulation of type II interferon production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-1 production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-2 production	Bile acid receptor	Homo sapiens (human)
negative regulation of interleukin-6 production	Bile acid receptor	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Bile acid receptor	Homo sapiens (human)
positive regulation of interleukin-17 production	Bile acid receptor	Homo sapiens (human)
toll-like receptor 9 signaling pathway	Bile acid receptor	Homo sapiens (human)
regulation of urea metabolic process	Bile acid receptor	Homo sapiens (human)
intracellular triglyceride homeostasis	Bile acid receptor	Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulus	Bile acid receptor	Homo sapiens (human)
bile acid signaling pathway	Bile acid receptor	Homo sapiens (human)
intracellular bile acid receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
cholesterol homeostasis	Bile acid receptor	Homo sapiens (human)
defense response to bacterium	Bile acid receptor	Homo sapiens (human)
negative regulation of apoptotic process	Bile acid receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Bile acid receptor	Homo sapiens (human)
innate immune response	Bile acid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bile acid receptor	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	Bile acid receptor	Homo sapiens (human)
fatty acid homeostasis	Bile acid receptor	Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulus	Bile acid receptor	Homo sapiens (human)
regulation of bile acid biosynthetic process	Bile acid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Bile acid receptor	Homo sapiens (human)
cellular response to fatty acid	Bile acid receptor	Homo sapiens (human)
cellular response to organonitrogen compound	Bile acid receptor	Homo sapiens (human)
negative regulation of monocyte chemotactic protein-1 production	Bile acid receptor	Homo sapiens (human)
regulation of cholesterol metabolic process	Bile acid receptor	Homo sapiens (human)
cellular response to bile acid	Bile acid receptor	Homo sapiens (human)
positive regulation of adipose tissue development	Bile acid receptor	Homo sapiens (human)
positive regulation of phosphatidic acid biosynthetic process	Bile acid receptor	Homo sapiens (human)
positive regulation of glutamate metabolic process	Bile acid receptor	Homo sapiens (human)
positive regulation of ammonia assimilation cycle	Bile acid receptor	Homo sapiens (human)
cell differentiation	Bile acid receptor	Homo sapiens (human)
negative regulation of inflammatory response	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Bile acid receptor	Homo sapiens (human)
transcription coregulator binding	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Bile acid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Bile acid receptor	Homo sapiens (human)
nuclear receptor activity	Bile acid receptor	Homo sapiens (human)
protein binding	Bile acid receptor	Homo sapiens (human)
zinc ion binding	Bile acid receptor	Homo sapiens (human)
nuclear receptor binding	Bile acid receptor	Homo sapiens (human)
bile acid binding	Bile acid receptor	Homo sapiens (human)
bile acid receptor activity	Bile acid receptor	Homo sapiens (human)
sequence-specific DNA binding	Bile acid receptor	Homo sapiens (human)
nuclear retinoid X receptor binding	Bile acid receptor	Homo sapiens (human)
chenodeoxycholic acid binding	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoplasm	Bile acid receptor	Homo sapiens (human)
chromatin	Bile acid receptor	Homo sapiens (human)
euchromatin	Bile acid receptor	Homo sapiens (human)
receptor complex	Bile acid receptor	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Bile acid receptor	Homo sapiens (human)
nucleus	Bile acid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1486647	Apparent permeability from basolateral to apical side in human Caco2 cells at 50 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893168	Agonist activity at human FXR transfected in CHO-K1 cells coexpressed with beta-galactosidase assessed as maximum relative efficacy at 3.3 uM incubated for 3 to 16 hrs by PathHunter chemiluminescence based assay relative to GW4064	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893195	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as reduction in liver fibrosis at 80 mg/kg, po administered daily for 4 weeks by picrosirius red staining method	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID240037	Effective concentration against farnesoid X receptor (FXR)	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
AID1486666	Induction of FXR activation in C57BL/6 mouse ileum assessed as reduction in FXR-mediated Cyp7A1 mRNA expression at 100 mg/kg, ig for 5 days by PCR method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893165	Agonist activity at human FXR transfected in CHO-K1 cells coexpressed with beta-galactosidase incubated for 3 to 16 hrs by PathHunter chemiluminescence based assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID254620	Effective concentration towards farnesoid X receptor (FXR)	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID1486650	Drug accumulation in C57BL/6 mouse ileum at 100 mg/kg, ig for 5 days by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486644	Apparent permeability from apical side to basolateral side in human Caco2 cells at 20 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID512618	Agonist activity at FXR	2005	Nature chemical biology, Jul, Volume: 1, Issue:2	Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
AID1486652	Drug accumulation in C57BL/6 mouse liver at 100 mg/kg, ig for 5 days by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893188	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of IBABP gene expression at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1486651	Drug accumulation in C57BL/6 mouse jejunum at 100 mg/kg, ig for 5 days by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486665	Induction of FXR activation in C57BL/6 mouse ileum assessed as increase in FXR-mediated Bsep mRNA expression at 100 mg/kg, ig for 5 days by PCR method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486649	Efflux ratio in human Caco2 cells at 50 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893201	Effect on serum LDL-cholesterol level in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model at 80 mg/kg, po administered daily for 4 weeks by microplate reader assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1486653	Drug accumulation in C57BL/6 mouse serum at 100 mg/kg, ig for 5 days by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486667	Binding affinity to FXR (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486643	Drug uptake in human Caco2 cells at 20 and 50 uM by LC-MS/MS method relative to initial level	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893192	Toxicity in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as change in amount of food intake at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893186	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of FGF15 gene expression at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893200	Effect on serum HDL-cholesterol level in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model at 80 mg/kg, po administered daily for 4 weeks by microplate reader assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893187	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of SHP gene expression at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893191	Toxicity in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as change in body weight at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1486645	Apparent permeability from apical side to basolateral side in human Caco2 cells at 50 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1486648	Efflux ratio in human Caco2 cells at 20 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893194	Toxicity in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as increase in liver wet weight at 80 mg/kg, po administered daily for 4 weeks by picrosirius red staining method	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID254619	Effective concentration against farnesoid X receptor (FXR)	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID694036	Agonist activity at FXR	2012	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22	Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
AID1486641	Drug uptake in human Caco2 cells at 20 and 50 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893189	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of OST-alpha gene expression at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1893193	Invivo activation of FXR in SCDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as improved glucose tolerance measured up to 120 mins by glucose tolerance test	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1486646	Apparent permeability from basolateral to apical side in human Caco2 cells at 20 uM by LC-MS/MS method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	A novel intestinal-restricted FXR agonist.
AID1893190	Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of SHP gene expression in liver at 80 mg/kg, po administered daily for 4 weeks	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery of (
AID1346766	Human Farnesoid X receptor (1H. Liver X receptor-like receptors)	2003	Molecular cell, Apr, Volume: 11, Issue:4	A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (33.33)	29.6817
2010's	9 (42.86)	24.3611
2020's	5 (23.81)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	6 (28.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (71.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.41	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
aldosterone [no description available]	2.41	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.41	1	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.17	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	4.56	4	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.41	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.02	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.	3.12	1	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
cholic acid Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.	2.05	1	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.31	1	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
obeticholic acid obeticholic acid: A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.. obeticholic acid : A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis.	3.12	1	3alpha-hydroxy steroid; 7alpha-hydroxy steroid; dihydroxy-5beta-cholanic acid	farnesoid X receptor agonist; hepatoprotective agent
epothilone b [no description available]	2.02	1	epothilone; epoxide	antineoplastic agent; apoptosis inducer; microtubule-stabilising agent
epothilone a Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).	2.02	1	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
alitretinoin Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.	2.41	1	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.41	1	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
purmorphamine purmorphamine: structure in first source. purmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group.	3.12	1	aromatic ether; morpholines; purines; secondary amino compound	osteogenesis regulator; SMO receptor agonist
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.02	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
ophiocordin azepinostatin: isolated from Fusarium merismoides; structure in first source; RN assigned by CAS - 63590-19-2 (ophiocordin; azepinostatin is not the same as ophiocordin)	2.02	1
sarcodictyin a sarcodictyin A: structure in first source	2.02	1
psammaplin a psammaplin A: isolated from marine sponges Poecillastra and Jaspis; structure in second source	2.02	1
pregna-4,17-diene-3,16-dione pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor	3.17	1	3-hydroxy steroid	androgen
l-165041 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.	2.41	1	aromatic ketone
tubacin tubacin: inhibits histone deacetylase 6; structure in first source	3.12	1	1,3-oxazoles
tws 119 [no description available]	3.12	1	pyrroles
gw 4064 [no description available]	3.91	3	stilbenoid
hamigeran b hamigeran B: has antiviral activity; structure in first source	2.02	1
way-362450 [no description available]	3.17	1	indoles
apicularen a apicularen A: isolated from Chondromyces; structure in first source	2.02	1
brevetoxin b brevetoxin B: from dinoflagellate Gymnodinium breve	2.02	1	ciguatoxin
103d5r 103D5R: small-molecule inhibitor of the hypoxia-inducible factor 1 pathway; structure in first source	2.02	1
cardiogenol c cardiogenol C: structure in first source	3.12	1	methoxybenzenes; substituted aniline
somatostatin [no description available]	2.02	1	heterodetic cyclic peptide; peptide hormone
cholestyramine resin Cholestyramine Resin: A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.	2.05	1

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Fatty Liver, Nonalcoholic [description not available]	2.41	1
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.41	1
Bowel Diseases, Inflammatory [description not available]	2.31	1
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	2.31	1
Colorectal Cancer [description not available]	3.23	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.23	1
Caliciviridae Infections Virus diseases caused by CALICIVIRIDAE. They include HEPATITIS E; VESICULAR EXANTHEMA OF SWINE; acute respiratory infections in felines, rabbit hemorrhagic disease, and some cases of gastroenteritis in humans.	2.17	1
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	2.17	1
Alloxan Diabetes [description not available]	2.17	1
Insulin Sensitivity [description not available]	3.96	4
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	3.96	4
Weight Gain Increase in BODY WEIGHT over existing weight.	2.82	3
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	3.73	3
Bile Duct Obstruction [description not available]	2.93	1
Hyperlipemia [description not available]	2.93	1
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	2.93	1
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.93	1

fexaramine

Description

Cross-References

Synonyms (46)

Drug Classes (1)

Protein Targets (2)

Potency Measurements

Activation Measurements

Biological Processes (48)

Molecular Functions (15)

Ceullar Components (6)

Bioassays (37)

Research

Studies (21)

Market Indicators

Research Demand Index: 34.08

Study Types

fexaramine

Description

Cross-References

Synonyms (46)

Drug Classes (1)

Protein Targets (2)

Potency Measurements

Activation Measurements

Biological Processes (48)

Molecular Functions (15)

Ceullar Components (6)

Bioassays (37)

Research

Studies (21)

Market Indicators

Research Demand Index: 34.08

Study Types

Related Drugs (33)

Related Conditions (20)